Noninfectious Retrovirus Particles Drive the / Dependent Neutralizing Antibody Response

English version České info

Members of the APOBEC3 family of deoxycytidine deaminases counteract a broad range of retroviruses in vitro through an indirect mechanism that requires virion incorporation and inhibition of reverse transcription and/or hypermutation of minus strand transcripts in the next target cell. The selective advantage to the host of this indirect restriction mechanism remains unclear, but valuable insights may be gained by studying APOBEC3 function in vivo. Apobec3 was previously shown to encode Rfv3, a classical resistance gene that controls the recovery of mice from pathogenic Friend retrovirus (FV) infection by promoting a more potent neutralizing antibody (NAb) response. The underlying mechanism does not involve a direct effect of Apobec3 on B cell function. Here we show that while Apobec3 decreased titers of infectious virus during acute FV infection, plasma viral RNA loads were maintained, indicating substantial release of noninfectious particles in vivo. The lack of plasma virion infectivity was associated with a significant post-entry block during early reverse transcription rather than G-to-A hypermutation. The Apobec3-dependent NAb response correlated with IgG binding titers against native, but not detergent-lysed virions. These findings indicate that innate Apobec3 restriction promotes NAb responses by maintaining high concentrations of virions with native B cell epitopes, but in the context of low virion infectivity. Finally, Apobec3 restriction was found to be saturable in vivo, since increasing FV inoculum doses resulted in decreased Apobec3 inhibition. By analogy, maximizing the release of noninfectious particles by modulating APOBEC3 expression may improve humoral immunity against pathogenic human retroviral infections.

Vyšlo v časopise: Noninfectious Retrovirus Particles Drive the / Dependent Neutralizing Antibody Response. PLoS Pathog 7(10): e32767. doi:10.1371/journal.ppat.1002284
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002284

Souhrn

Zdroje

1. StremlauMOwensCMPerronMJKiesslingMAutissierP 2004 The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427 848 853

2. NeilSJZangTBieniaszPD 2008 Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451 425 430

3. LaguetteNSobhianBCasartelliNRingeardMChable-BessiaC 2011 SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474 654 657

4. SheehyAMGaddisNCChoiJDMalimMH 2002 Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 646 650

5. MarianiRChenDSchrofelbauerBNavarroFKonigR 2003 Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114 21 31

6. MbisaJLBarrRThomasJAVandegraaffNDorweilerIJ 2007 HIV-1 cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration. J Virol 81 7099 7110

7. BishopKNVermaMKimEYWolinskySMMalimMH 2008 APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4 e1000231

8. OkeomaCMLovsinNPeterlinBMRossSR 2007 APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445 927 930

9. BrowneEPLittmanDR 2008 Species-specific restriction of apobec3-mediated hypermutation. J Virol 82 1305 1313

10. LangloisMAKemmerichKRadaCNeubergerMS 2009 The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3. J Virol 83 11550 11559

11. PetitVGuetardDRenardMKerielASitbonM 2009 Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo. J Mol Biol 385 65 78

12. PaceCKellerJNolanDJamesIGaudieriS 2006 Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 80 9259 9269

13. KiefferTLKwonPNettlesREHanYRaySC 2005 G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 79 1975 1980

14. KnoepfelSADi GiallonardoFDaumerMThielenAMetznerKJ 2011 In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing. J Virol Methods 171 329 328

15. HacheGShindoKAlbinJSHarrisRS 2008 Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr Biol 18 819 824

16. OkeomaCMHuegelALLingappaJFeldmanMDRossSR 2010 APOBEC3 Proteins Expressed in Mammary Epithelial Cells Are Packaged into Retroviruses and Can Restrict Transmission of Milk-Borne Virions. Cell Host Microbe 8 534 543

17. SantiagoMLGreeneWC 2008 The role of the Apobec3 family of cytidine deaminases in innate immunity, G-to-A hypermutation and evolution of retroviruses. DomingoEParrishCRHollandJJ Origin and Evolution of Viruses London, UK Academic Press 183 206

18. MiklMCWattINLuMReikWDaviesSL 2005 Mice deficient in APOBEC2 and APOBEC3. Mol Cell Biol 25 7270 7277

19. LowAOkeomaCMLovsinNde las HerasMTaylorTH 2009 Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology 385 455 463

20. SantiagoMLMontanoMBenitezRMesserRJYonemotoW 2008 Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321 1343 1346

21. TakedaETsuji-KawaharaSSakamotoMLangloisMANeubergerMS 2008 Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol 82 10998 11008

22. ChesebroBMiyazawaMBrittWJ 1990 Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol 8 477 499

23. HasenkrugKJDittmerU 2007 Immune control and prevention of chronic Friend retrovirus infection. Front Biosci 12 1544 1551

24. ChesebroBWehrlyK 1979 Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A 76 425 429

25. DoigDChesebroB 1979 Anti-Friend virus antibody is associated with recovery from viremia and loss of viral leukemia cell-surface antigens in leukemic mice. Identification of Rfv-3 as a gene locus influencing antibody production. J Exp Med 150 10 19

26. SantiagoMLSmithDSBarrettBSMontanoMBenitezRL 2011 Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor. J Virol 85 189 199

27. Tsuji-KawaharaSChikaishiTTakedaEKatoMKinoshitaS 2010 Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in friend virus-infected mice. J Virol 84 6082 6095

28. SantiagoMLBenitezRLMontanoMHasenkrugKJGreeneWC 2010 Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. J Immunol 185 1114 1123

29. OkeomaCMPetersenJRossSR 2009 Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection. J Virol 83 3029 3038

30. MuramatsuMKinoshitaKFagarasanSYamadaSShinkaiY 2000 Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102 553 563

31. StopakKde NoronhaCYonemotoWGreeneWC 2003 HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12 591 601

32. SheehyAMGaddisNCMalimMH 2003 The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9 1404 1407

33. MarinMRoseKMKozakSLKabatD 2003 HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9 1398 1403

34. ZhengYHIrwinDKurosuTTokunagaKSataT 2004 Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 78 6073 6076

35. SimonVZennouVMurrayDHuangYHoDD 2005 Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 1 e6

36. JinXBrooksAChenHBennettRReichmanR 2005 APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 79 11513 11516

37. UlengaNKSarrADThakore-MeloniSSankaleJLEisenG 2008 Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. J Infect Dis 198 486 492

38. SuiYZhuQGagnonSDzutsevATerabeM 2010 Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A 107 9843 9848

39. RobertsonMNMiyazawaMMoriSCaugheyBEvansLH 1991 Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods 34 255 271

40. HeJYChengHJWangYFZhuYTLiGQ 2008 Development of a real-time quantitative reverse transcriptase PCR assay for detection of the Friend leukemia virus load in murine plasma. J Virol Methods 147 345 350

41. MahieuxRSuspeneRDelebecqueFHenryMSchwartzO 2005 Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J Gen Virol 86 2489 2494

42. SuspeneRGuetardDHenryMSommerPWain-HobsonS 2005 Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A 102 8321 8326

43. DoitshGCavroisMLassenKGZepedaOYangZ 2010 Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 143 789 801

44. ChesebroBBrittWEvansLWehrlyKNishioJ 1983 Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology 127 134 148

45. VoltersvikPAlbrektsenGUlvestadEDyrhol-RiiseAMSorensenB 2003 Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremia. J Acquir Immune Defic Syndr 34 358 367

46. MorrisLBinleyJMClasBABonhoefferSAstillTP 1998 HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 188 233 245

47. BinleyJMTrkolaAKetasTSchillerDClasB 2000 The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis 182 945 949

48. BachmannMFJenningsGT 2010 Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10 787 796

49. MesserRJDittmerUPetersonKEHasenkrugKJ 2004 Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci U S A 101 12260 12265

50. BrittWJChesebroB 1983 Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol 130 2363 2367

51. YangXKurtevaSRenXLeeSSodroskiJ 2005 Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol 79 12132 12147

52. FassDHarrisonSCKimPS 1996 Retrovirus envelope domain at 1.7 angstrom resolution. Nat Struct Biol 3 465 469

53. ReinhardtRLLiangHELocksleyRM 2009 Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 10 385 393

54. ForsellMNSchiefWRWyattRT 2009 Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr Opin HIV AIDS 4 380 387

55. YoungKRMcBurneySPKarkhanisLURossTM 2006 Virus-like particles: designing an effective AIDS vaccine. Methods 40 98 117

56. SchmittKHillMSRuizACulleyNPinsonDM 2009 Mutations in the highly conserved SLQYLA motif of Vif in a simian-human immunodeficiency virus result in a less pathogenic virus and are associated with G-to-A mutations in the viral genome. Virology 383 362 372

57. KolokithasARosenkeKMalikFHendrickDSwansonL 2010 The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3. J Virol 84 10933 10936

58. KoningFANewmanENKimEYKunstmanKJWolinskySM 2009 Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 83 9474 9485

59. ChenKHuangJZhangCHuangSNunnariG 2006 Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 80 7645 7657

60. PengGLeiKJJinWGreenwell-WildTWahlSM 2006 Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 203 41 46

61. Adalid-PeraltaLGodotVColinCKrzysiekRTranT 2008 Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection. J Leukoc Biol 83 1060 1067

62. BestSLe TissierPTowersGStoyeJP 1996 Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 382 826 829

63. LillyFSteevesRA 1973 B-tropic Friend virus: a host-range pseudotype of spleen focus-forming virus (SFFV). Virology 55 363 370

64. RobertsonSJAmmannCGMesserRJCarmodyABMyersL 2008 Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with lactate dehydrogenase-elevating virus. J Virol 82 408 418

65. MarquesRAntunesIEksmondUStoyeJHasenkrugK 2008 B lymphocyte activation by coinfection prevents immune control of friend virus infection. J Immunol 181 3432 3440

66. LavignonMWalkerJLPerrymanSMMalikFGKhanAS 1994 Characterization of epitopes defining two major subclasses of polytropic murine leukemia viruses (MuLVs) which are differentially expressed in mice infected with different ecotropic MuLVs. J Virol 68 5194 5203

67. YuQKonigRPillaiSChilesKKearneyM 2004 Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11 435 442

68. SandersRWVesanenMSchuelkeNMasterASchiffnerL 2002 Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76 8875 8889

69. PantophletRWangMAguilar-SinoROBurtonDR 2009 The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions. J Virol 83 1649 1659